PKO Investment Management Joint Stock Co Has $1.56 Million Position in Elevance Health, Inc. $ELV

PKO Investment Management Joint Stock Co boosted its position in shares of Elevance Health, Inc. (NYSE:ELV) by 11.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,000 shares of the company’s stock after purchasing an additional 400 shares during the quarter. PKO Investment Management Joint Stock Co’s holdings in Elevance Health were worth $1,556,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of ELV. GAMMA Investing LLC boosted its holdings in shares of Elevance Health by 88.1% in the first quarter. GAMMA Investing LLC now owns 3,390 shares of the company’s stock valued at $1,475,000 after buying an additional 1,588 shares during the period. Oppenheimer & Co. Inc. lifted its stake in shares of Elevance Health by 2.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 5,744 shares of the company’s stock worth $2,498,000 after buying an additional 123 shares during the last quarter. Golden State Wealth Management LLC increased its position in Elevance Health by 129.2% during the first quarter. Golden State Wealth Management LLC now owns 463 shares of the company’s stock worth $202,000 after acquiring an additional 261 shares during the period. Pure Financial Advisors LLC increased its position in Elevance Health by 5.1% during the first quarter. Pure Financial Advisors LLC now owns 1,973 shares of the company’s stock worth $858,000 after acquiring an additional 95 shares during the period. Finally, Sequoia Financial Advisors LLC increased its holdings in Elevance Health by 15.7% in the 1st quarter. Sequoia Financial Advisors LLC now owns 6,717 shares of the company’s stock valued at $2,922,000 after buying an additional 913 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Insider Activity

In related news, Director Susan D. Devore acquired 1,200 shares of the business’s stock in a transaction that occurred on Tuesday, August 19th. The stock was bought at an average cost of $312.15 per share, for a total transaction of $374,580.00. Following the purchase, the director owned 3,502 shares in the company, valued at $1,093,149.30. The trade was a 52.13% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.29% of the company’s stock.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $342.45 on Friday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The business has a 50-day simple moving average of $327.09 and a two-hundred day simple moving average of $353.39. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.44 and a current ratio of 1.56. The firm has a market cap of $76.11 billion, a price-to-earnings ratio of 14.00, a price-to-earnings-growth ratio of 1.26 and a beta of 0.59.

Elevance Health (NYSE:ELV) last issued its earnings results on Tuesday, October 21st. The company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.03 by $1.00. Elevance Health had a return on equity of 16.17% and a net margin of 2.84%.The business had revenue of $50.09 billion during the quarter, compared to analyst estimates of $49.26 billion. During the same quarter in the previous year, the firm earned $8.37 EPS. Elevance Health’s revenue was up 12.0% on a year-over-year basis. On average, analysts expect that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 19th. Investors of record on Friday, December 5th will be paid a dividend of $1.71 per share. The ex-dividend date is Friday, December 5th. This represents a $6.84 dividend on an annualized basis and a dividend yield of 2.0%. Elevance Health’s payout ratio is 27.96%.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Elevance Health in a research note on Friday. Sanford C. Bernstein lowered their target price on shares of Elevance Health from $445.00 to $420.00 and set an “outperform” rating for the company in a report on Thursday, October 16th. Guggenheim raised their price objective on shares of Elevance Health from $360.00 to $398.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Friday, July 18th. Finally, Bank of America lifted their price target on shares of Elevance Health from $330.00 to $370.00 and gave the stock a “neutral” rating in a research note on Friday, October 10th. Twelve investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $397.89.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.